P62+ hyaline inclusions in intrahepatic cholangiocarcinoma associated with viral hepatitis or alcoholic liver disease

American Journal of Clinical Pathology

Volumn 134, Issue 3, 2010, Pages 457-465

  Aishima, Shinichi ^a   Fujita, Nobuhiro ^a   Mano, Yohei ^a   Iguchi, Tomohiro ^a   Taketomi, Akinobu ^a   Maehara, Yoshihiko ^a   Oda, Yoshinao ^a   Tsuneyoshi, Masazumi ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Hyaline globule; Mallory body; p62; Ubiquitin

Indexed keywords

HEPATITIS B ANTIGEN; HEPATITIS C ANTIBODY; HYALIN; PROTEIN P62;

ADULT; AGED; ALCOHOL LIVER DISEASE; ARTICLE; BILE DUCT CARCINOMA; CONTROLLED STUDY; DISEASE ASSOCIATION; ELECTRON MICROSCOPY; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MALLORY BODY; PRIORITY JOURNAL; TUMOR LOCALIZATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; AGED, 80 AND OVER; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CASE-CONTROL STUDIES; CHOLANGIOCARCINOMA; FEMALE; HEPATITIS, VIRAL, HUMAN; HUMANS; HYALIN; INCLUSION BODIES; LIVER DISEASES, ALCOHOLIC; MALE; MIDDLE AGED;

EID: 77956578400     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCP53YVVJCNDZIR     Document Type: Article

References (49)

1. Denk H, Stumptner C, Zatloukal K. Mallory bodies revisited. J Hepatol. 2000;32:689-702.
2. Stumptner C, Heid H, Fuchsbichler A, et al. Analysis of intracytoplasmic hyaline bodies in a hepatocellular carcinoma: demonstration of p62 as major constituent. Am J Pathol. 1999;154:1701-1710.
3. Fickert P, Trauner M, Fuchsbichler A, et al. Mallory body formation in primary biliary cirrhosis is associated with increased amounts and abnormal phosphorylation and ubiquitination of cytokeratins. J Hepatol. 2003;38:387-394. (Pubitemid 36399238)
4. Zatloukal K, Stumptner C, Fuchsbichler A, et al. p62 is a common component of cytoplasmic inclusions in protein aggregation diseases. Am J Pathol. 2002;160:255-263.
5. Hoso M, Nakanuma Y. Clinicopathological characteristics of hepatocellular carcinoma bearing Mallory bodies: an autopsy study. Liver. 1990;10:264-268. (Pubitemid 20351248)
6. Norkin SA, Campagna-Pinto D. Cytoplasmic hyaline inclusions in hepatoma: histochemical study. Arch Pathol. 1968;86:25-32.
7. Cohen C. Intracytoplasmic hyaline globules in hepatocellular carcinomas. Cancer. 1976;37:1754-1758.
8. Enat R, Buschmann RJ, Chomet B. Ultrastructure of cytoplasmic hyaline inclusions in a case of human hepatocarcinoma. Gastroenterology. 1973;65:802-810.
9. Grimelius L, Stenram U, Westman J, et al. Hyaline cytoplasmic inclusions in human hepatoma: a case report. Acta Cytol. 1977;21:469-476.
10. An T, Ghatak N, Kastner R, et al. Hyaline globules and intracellular lumina in a hepatocellular carcinoma. Am J Clin Pathol. 1983;79:392-396.
11. Linnoila RI, Keiser HR, Steinberg SM, et al. Histopathology of benign versus malignant sympathoadrenal paragangliomas: clinicopathologic study of 120 cases including unusual histologic features. Hum Pathol. 1990;21:1168-1180.
12. Michel RP, Limacher JJ, Kimoff RJ. Mallory bodies in scar adenocarcinoma of the lung. Hum Pathol. 1982;13:81-85.
13. Dekker A, Krause JR. Hyaline globules in human neoplasms: a report of three autopsy cases. Arch Pathol. 1973;95:178-181.
14. Jagirdar J, Irie T, French SW, et al. Globular Mallory-like bodies in renal cell carcinoma: report of a case and review of cytoplasmic eosinophilic globules. Hum Pathol. 1985;16:949-952. (Pubitemid 15238277)
15. Sanz L, Sanchez P, Lallena MJ, et al. The interaction of p62 with RIP links the atypical PKCs to NF-kappaB activation. EMBO J. 1999;18:3044-3053.
16. Geetha T, Wooten MW. Structure and functional properties of the ubiquitin binding protein p62. FEBS Lett. 2002;512:19-24.
17. Denk H, Stumptner C, Fuchsbichler A, et al. Are the Mallory bodies and intracellular hyaline bodies in neoplastic and non-neoplastic hepatocytes related? J Pathol. 2006;208:653-661.
18. Zatloukal K, Stumptner C, Lehner M, et al. Cytokeratin 8 protects from hepatotoxicity, and its ratio to cytokeratin 18 determines the ability of hepatocytes to form Mallory bodies. Am J Pathol. 2000;156:1263-1274.
19. Stumptner C, Fuchsbichler A, Heid H, et al. Mallory body: a disease-associated type of sequestosome. Hepatology. 2002;35:1053-1062. (Pubitemid 34454002)
20. Nakamichi I, Toivola DM, Strnad P, et al. Keratin 8 overexpression promotes mouse Mallory body formation. J Cell Biol. 2005;171:931-937.
21. Nan L, Wu Y, Bardag-Gorce F, et al. p62 is involved in the mechanism of Mallory body formation. Exp Mol Pathol. 2004;77:168-175.
22. Stumptner C, Fuchsbichler A, Zatloukal K, et al. In vitro production of Mallory bodies and intracellular hyaline bodies: the central role of sequestosome 1/p62. Hepatology. 2007;46:851-860. (Pubitemid 47439764)
23. Zhang JY, Megliorino R, Peng XX, et al. Antibody detection using tumor-associated antigen mini-array in immunodiagnosing human hepatocellular carcinoma. J Hepatol. 2007;46:107-114.
24. Lu M, Nakamura RM, Dent ED, et al. Aberrant expression of fetal RNA-binding protein p62 in liver cancer and liver cirrhosis. Am J Pathol. 2001;159:945-953.
25. Qian HL, Peng XX, Chen SH, et al. p62 expression in primary carcinomas of the digestive system. World J Gastroenterol. 2005;11:1788-1792. (Pubitemid 40520769)
26. Su Y, Qian H, Zhang J, et al. The diversity expression of p62 in digestive system cancers. Clin Immunol. 2005;116:118-123. (Pubitemid 40910237)
27. Rolland P, Madjd Z, Durrant L, et al. The ubiquitin-binding protein p62 is expressed in breast cancers showing features of aggressive disease. Endocr Relat Cancer. 2007;14:73-80.
28. Nakanuma Y, Sripa B, Vatanasapt V. Intrahepatic cholangiocarcinoma. In: Hamilton SR, Aaltonen LA, eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Digestive System. Lyon, France: IARC Press; 2000:173-180.
29. Aishima S, Kuroda Y, Nishihara Y, et al. Proposal of progression model for intrahepatic cholangiocarcinoma: clinicopathologic differences between hilar type and peripheral type. Am J Surg Pathol. 2007;31:1059-1067.
30. Scheimberg I, Cullinane C, Kelsey A, et al. Primary hepatic malignant tumor with rhabdoid features: a histological, immunocytochemical, and electron microscopic study of four cases and a review of the literature. Am J Surg Pathol. 1996;20:1394-1400. (Pubitemid 26367211)
31. Agaram NP, Baren A, Antonescu CR. Pediatric and adult hepatic embryonal sarcoma: a comparative ultrastructural study with morphologic correlations. Ultrastruct Pathol. 2006;30:403-408.
32. Ishak KG, Glunz PR. Hepatoblastoma and hepatocarcinoma in infancy and childhood: report of 47 cases. Cancer. 1967;20:396-422.
33. Keeley AF, Iseri OA, Gottlieb LS. Ultrastructure of hyaline cytoplasmic inclusions in a human hepatoma: relationship to Mallory's alcoholic hyalin. Gastroenterology. 1972;62:280-293.
34. MacDonald K, Bedard YC. Cytologic, ultrastructural and immunologic features of intracytoplasmic hyaline bodies in fine needle aspirates of hepatocellular carcinoma. Acta Cytol. 1990;34:197-200. (Pubitemid 20126119)
35. Shaib YH, El-Serag HB, Davila JA, et al. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology. 2005;128:620-626.
36. Lee TY, Lee SS, Jung SW, et al. Hepatitis B virus infection and intrahepatic cholangiocarcinoma in Korea: a case-control study. Am J Gastroenterol. 2008;103:1716-1720.
37. Zhou YM, Yin ZF, Yang JM, et al. Risk factors for intrahepatic cholangiocarcinoma: a case-control study in China. World J Gastroenterol. 2008;14:632-635.
38. Donato F, Gelatti U, Tagger A, et al. Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in Italy. Cancer Causes Control. 2001;12:959-964.
39. Kobayashi M, Ikeda K, Saitoh S, et al. Incidence of primary cholangiocellular carcinoma of the liver in Japanese patients with hepatitis C virus - related cirrhosis. Cancer. 2000;88:2471-2477.
40. Shaib YH, El-Serag HB, Nooka AK, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospital-based case-control study. Am J Gastroenterol. 2007;102:1016-1021.
41. Yamada S, Takezawa J, Takagi H, et al. Histologic features and bile duct lesions in the alcoholic. Jpn J Med. 1985;24:223-230. (Pubitemid 16231872)
42. Torbenson M, Yeh MM, Abraham SC. Bile duct dysplasia in the setting of chronic hepatitis C and alcohol cirrhosis. Am J Surg Pathol. 2007;31:1410-1413.
43. Seitz HK, Stickel F. Risk factors and mechanisms of hepatocarcinogenesis with special emphasis on alcohol and oxidative stress. Biol Chem. 2006;387:349-360.
44. Lai MM. Hepatitis C virus proteins: direct link to hepatic oxidative stress, steatosis, carcinogenesis and more. Gastroenterology. 2002;122:568-571.
45. Grossi S, Sumberaz A, Gosmar M, et al. DNA damage in peripheral blood lymphocytes of patients with cirrhosis related to alcohol abuse or to hepatitis B and C viruses. Eur J Gastroenterol Hepatol. 2008;20:22-25. (Pubitemid 350307483)
46. Fataccioli V, Andraud E, Gentil M, et al. Effects of chronic ethanol administration on rat liver proteasome activities: relationship with oxidative stress. Hepatology. 1998;29:14-20.
47. James OFW, Day CP. Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance. J Hepatol. 1998;29:495-501.
48. Johnston JA, Ward CL, Kopito RR. Aggresomes: a cellular response to misfolded proteins. J Cell Biol. 1998;143:1883-1898.
49. Ishii T, Itoh K, Sato H, et al. Oxidative stress - inducible proteins in macrophages. Free Radic Res. 1999;31:351-355. (Pubitemid 29452861)